Uptake of COVID-19 Booster Dose among Saudi Arabian Population

Backgroundand objectives: Although several vaccines have been produced and administered around the world, new SARS-CoV-2 worsened the COVID-19 infection risk and impacted the initial vaccine dosage effectiveness. Based on studies indicating that the third and fourth COVID-19 vaccine doses significan...

Descripción completa

Detalles Bibliográficos
Autores principales: Alshahrani, Najim Z., Alsabaani, Abdullah A., Ridda, Iman, Rashid, Harunor, Alzahrani, Faris, Almutairi, Talal Hamed, Alzahrani, Bader Ahmed S., Albeshri, Abdulelah Saleh Saeed
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9323634/
https://www.ncbi.nlm.nih.gov/pubmed/35888690
http://dx.doi.org/10.3390/medicina58070972
Descripción
Sumario:Backgroundand objectives: Although several vaccines have been produced and administered around the world, new SARS-CoV-2 worsened the COVID-19 infection risk and impacted the initial vaccine dosage effectiveness. Based on studies indicating that the third and fourth COVID-19 vaccine doses significantly reduced COVID-19 transmission, Saudi Arabia has been administering COVID-19 booster vaccine doses to its citizens. The purpose of this study was to evaluate the uptake of the COVID-19 vaccine booster in relation to the socio-demographic characteristics and other associated factors among the Saudi population. Materials and Methods: This study was an online analytical cross-sectional study using a self-administered questionnaire. Pearson Chi-square test and multiple logistic regression analyses were used to determine factors associated with the uptake of COVID-19 booster dose vaccines. Results: A total of 2332 responded to our study. Overall, 527 (22.6%) participants had received a booster dose. An age of 55 and above (aOR: 5.415; 95% CI: 2.719–10.783), Eastern region (aOR: 2.513; 95% CI: 1.566–4.033), history of influenza vaccination at annual intervals (aOR: 2.387; 95% CI: 1.730–3.293), the first dose of Moderna vaccine (aOR: 1.324; 95% CI: 1.160–1.510), and cancer (aOR: 2.161; 95% CI: 1.218–3.879) were independent factors most associated with a higher uptake of the COVID-19 vaccine booster dose. In contrast, the second dose of Moderna vaccine (aOR: 0.794; 95% CI: 0.683–0.922), AstraZeneca vaccine (aOR: 0.691; 95% CI: 0.509–0.939), strong symptoms from side effects after the second dose of the COVID-19 vaccine (aOR: 0.615; 95% CI: 0.404–0.935) were independent factors most associated with a lower uptake of the COVID-19 vaccine booster dose. Conclusions: Our findings indicate low COVID-19 vaccine booster uptake. This necessitates the need for strategies to address discouraging factors of the COVID-19 vaccine booster dose uptake and engage the Saudi population to raise awareness about the importance of the booster dose.

Ejemplares similares